OBJECTIVES: To estimate the prevalence of stage 3-5 chronic kidney disease (CKD) in 2010, evaluate the presence of comorbidities, and describe treatment among CKD patients. METHODS: Data for patients with prevalent or incident CKD in 2010 (age ≥ 10 years at CKD diagnosis) were extracted from the UK General Practice Research Database.  Patients were identified using Read codes or eGFR values, and those with cancer, hemolytic anemia, or sickle cell disease were excluded. RESULTS: Among 3.16MM patients in GPRD, we identified 166,707 patients with incident or prevalent stage 3-5 CKD in 2010 (5.3% of population).  The majority of patients were stage 3 (92.5%; stage 4 = 6.3%, stage 5 = 1.2%), female (62.1%) and, 92.6% were ≥ 60 years (92.6%; 99.9% were above 20 years).  The most common comorbidities were hypertension (64.7%), cardiovascular disease (37.1%), hypercholesterolemia (25.2%), and diabetes (19.2%), each condition being significantly more prevalent than in the general population (16.2%, 8.4%, 9%,  and 5.5%, respectively).  With more advanced CKD, the presence of comorbidities increased: considering stage 3 to 5, the proportion of CKD patients with hypertension, CVD, hypercholesterolaemia and diabetes increased from 63.7% to 80%, 36.2% to 43.5%, 25.1% to 29.2%, and 18.4% to 33.1%, respectively.  The proportion of CKD patients receiving antihypertensive treatment or lipid-modifying therapy (LMT) also increased as stage advanced: 76.5% in stage 3 to 79.8% in stage 5 were receiving antihypertensive drugs, and 51.7% to 57.7% LMT.  Statins were the most commonly used LMT agent (>89% for all these three stages). CONCLUSIONS: Stage 3 to 5 CKD affected 166,707 patients covered by GPRD in 2010 (prevalence rate = 5.3%); most had stage 3 CKD (92.5%).  Diabetes, hypertension and cardiovascular disease became more common with more advanced CKD.  Antihypertensives and LMTs have been prescribed for a little over 75% and 50% patients, respectively, regardless of their CKD stage.